Jeffrey D Marrazzo
CIK 1631262 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ONCE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1300
PHILADELPHIA, PA 19104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRME | Director | — | $4.30 | — | $0 | 7 | 2026-06-08 |
| Spark Therapeutics, Inc. (ONCE) Delisted | CHIEF EXECUTIVE OFFICER | 0 | — | — | -$20.02M | 28 | 2019-12-17 |
Recent Filings · Page 2 of 4
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-01-17 | Spark Therapeutics, Inc. (ONCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-02 | Spark Therapeutics, Inc. (ONCE) Delisted | Exer (M) | +6,000 | $20.7K | EDGAR |
| 2018-01-22 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | +3,354 | -$83.2K | EDGAR |
| 2017-12-20 | Spark Therapeutics, Inc. (ONCE) Delisted | Exer (M) | +60,000 | $207.0K | EDGAR |
| 2017-11-13 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$1.36M | EDGAR |
| 2017-08-24 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$1.63M | EDGAR |
| 2017-08-15 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$1.07M | EDGAR |
| 2017-08-04 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$2.19M | EDGAR |
| 2017-07-07 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$348.9K | EDGAR |
| 2017-06-22 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$574.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.